Pilot Study Evaluating Somatostatin Receptor's PET Imaging to Detect Inflammatory Phases of Myocarditis
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
Infectious myocarditis are frequent, most of the time viral and can evolve to cardiac
insufficiency. The diagnosis is difficult because they can mime an acute coronary syndrome.
Approximately 10 % of patients with acute infarction suspected, have a normal angiography,
and half of them has in fact a myocarditis, as showed studies of cardiac MRI among which some
realized in our department . However, anomalies observed in MRI are not specific and it is
necessary to use multiple criterions. A new radiopharmaceutical, the 68Ga-DOTATOC, specific
of somatostatin's receptors which are over expressed by the inflammatory cells, has recently
showed the capacity to identify myocarditis, but only in a small group of 6 patients.
The investigators make assumptions:
1. this radiopharmaceutical is enough sensitive to detect most of the acute inflammatory
myocarditis which are identified by the MRI and
2. it could maybe allow to identify myocarditis with a persistent subacute or chronic
inflammation, which are difficult to identify with cardiac MRI, and it would be a new
information able to guide the medical decision.
Primary objectif: to determine if PET with 68Ga-DOTATOC is enough sensitive to identify
myocarditis in acute inflammatory phase by hospitalized patients with suspected acute
infarction and with normal angiography and who have a high probability of myocarditis
identified by MRI. Disease prevalence will be close to 100 % at baseline Secondary
objectives: 1. Estimate the frequency of inflammatory forms (subacute or chronicle), with a
68Ga-DOTATOC PET at 3 to 5 months from baseline, when classic signs of acute inflammatory
generally disappeared (CRP, Troponin-I, myocardial oedema in MRI).
2. Analyze the concordance of the results of 68Ga-DOTATOC TEP by two readers